Phase 1 Lung Cancer Trial, Recruiting (NCT07462377)

Phase 1 Lung Cancer Trial, Recruiting NCT07462377 Sponsor: EpiBiologics Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07462377 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Doctors expect you to live for more than 12 weeks at the time you join the trial.
You are able to carry out most daily activities, with at most some limitations due to your illness (this is measured by a standard doctor's scale called ECOG, scores 0–2).
You have been diagnosed with a specific type of lung cancer (NSCLC) or head and neck cancer (HNSCC), confirmed by a lab test on a tissue sample.
If you have lung cancer (NSCLC), your cancer must have a specific change in a gene called EGFR (a mutation, insertion, or deletion).
Your cancer has spread to nearby areas or to other parts of the body (locally advanced or metastatic).
Your liver, kidneys, and other organs are working well enough to participate (confirm with trial site).

Who may not be able to join:

You have another serious illness that is not well controlled.
You have cancer that has spread to the brain and is currently causing symptoms.
You have been diagnosed with another type of cancer within the last 3 years, unless it was fully treated with the goal of a cure and there are no signs of it remaining.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 30 June 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07462377

Sponsor: EpiBiologics

Phase: Phase 1

Status: Recruiting

Condition: Lung Cancer

More information: https://clinicaltrials.gov/study/NCT07462377

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Doctors expect you to live for more than 12 weeks at the time you join the trial.
You are able to carry out most daily activities, with at most some limitations due to your illness (this is measured by a standard doctor's scale called ECOG, scores 0–2).
You have been diagnosed with a specific type of lung cancer (NSCLC) or head and neck cancer (HNSCC), confirmed by a lab test on a tissue sample.
If you have lung cancer (NSCLC), your cancer must have a specific change in a gene called EGFR (a mutation, insertion, or deletion).
Your cancer has spread to nearby areas or to other parts of the body (locally advanced or metastatic).
Your liver, kidneys, and other organs are working well enough to participate (confirm with trial site).

Who may not be able to join:

You have another serious illness that is not well controlled.
You have cancer that has spread to the brain and is currently causing symptoms.
You have been diagnosed with another type of cancer within the last 3 years, unless it was fully treated with the goal of a cure and there are no signs of it remaining.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 30 June 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

EpiBiologics

Registry

ClinicalTrials.gov

Start date

31 March 2026

Est. completion

1 July 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Evaluation of the safety and tolerability of EPI-326; Determination of the recommended dose and schedule for EPI-326 administration

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov